keyword
MENU ▼
Read by QxMD icon Read
search

Tardive

keyword
https://www.readbyqxmd.com/read/28443349/pharmacotherapy-for-the-treatment-of-tardive-dyskinesia-in-schizophrenia-patients
#1
Daniel P Witter, Richard C Holbert, Uma Suryadevara
Tardive dyskinesia (TD) is an iatrogenic movement disorder most commonly observed in patients with psychotic disorders who are treated with dopamine blocking antipsychotic medications. Treatment options are limited, and recommendations for treatment are based on a relative scarcity of evidence. Areas covered: After briefly highlighting current mechanistic theories of TD, this review will discuss the evidence for a number of medications of several different classes that have been studied for the treatment of TD since the 1970s with an emphasis on placebo controlled trials when possible...
April 26, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28437058/psychotic-and-bipolar-disorders-antipsychotic-drugs
#2
Sarah D Holder, Alaina L Edmunds, Sherri Morgan
Antipsychotic drugs block dopamine receptors and are used to manage psychosis as well as other mental illnesses that may or may not have psychotic features, such as bipolar disorders and major depressive disorder. First-generation antipsychotic drugs are more likely to cause adverse effects such as extrapyramidal symptoms and tardive dyskinesia. Adverse effects of second-generation antipsychotic drugs typically are related to metabolic abnormalities such as weight gain, abnormal blood glucose levels, and elevated lipid levels...
April 2017: FP Essentials
https://www.readbyqxmd.com/read/28413650/clinical-features-of-hemodialysis-patients-treated-for-hepatocellular-carcinoma-comparison-between-resection-and-radiofrequency-ablation
#3
Atsushi Hiraoka, Takashi Kumada, Kojiro Michitaka, Hidenori Toyoda, Toshifumi Tada, Koichi Takaguchi, Kunihiko Tsuji, Ei Itobayashi, Daichi Takizawa, Masashi Hirooka, Yohei Koizumi, Hironori Ochi, Koji Joko, Yoshiyasu Kisaka, Yuko Shimizu, Kazuto Tajiri, Joji Tani, Tatsuya Taniguchi, Akiko Toshimori, Shinichi Fujioka
There is no consensus regarding which therapeutic option is better and/or safer for treating hemodialysis (HD) patients with hepatocellular carcinoma (HCC). The present study compared surgical resection (Hx) and radiofrequency ablation (RFA) with regard to therapeutic efficacy in HD patients with HCC. Of 108 HD patients with naïve HCC treated at 15 institutions between 1988 and 2014 enrolled in the present study, 58 fulfilled the up-to-7 criteria [7 as the sum of the size of the largest tumor (cm) and the number of tumors] and were treated with Hx (n=23) or RFA (n=35); their clinical features, complications and prognosis were assessed...
April 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28404690/pharmacologic-characterization-of-valbenazine-nbi-98854-and-its-metabolites
#4
Dimitri E Grigoriadis, Evan Smith, Sam R J Hoare, Ajay Madan, Haig Bozigian
The vesicular monoamine transporter 2 (VMAT2) is an integral presynaptic protein that regulates the packaging and subsequent release of dopamine and other monoamines from neuronal vesicles into the synapse. Valbenazine (NBI-98854), a novel compound that selectively inhibits VMAT2, is being developed for the treatment of tardive dyskinesia. Valbenazine is converted to two significant circulating metabolites in vivo, namely, (+)-α-dihydrotetrabenazine (R,R,R-DHTBZ) and a mono-oxy metabolite, NBI-136110. Radioligand binding studies were conducted to assess and compare valbenazine, tetrabenazine and their respective metabolites in their abilities to selectively and potently inhibit [(3)H]-DHTBZ binding to VMAT2 in rat striatal, rat forebrain, and human platelet homogenates...
April 12, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28394697/genetic-study-of-neuregulin-1-and-receptor-tyrosine-protein-kinase-erbb-4-in-tardive-dyskinesia
#5
Clement C Zai, Arun K Tiwari, Nabilah I Chowdhury, Zeynep Yilmaz, Vincenzo de Luca, Daniel J Müller, Steven G Potkin, Jeffrey A Lieberman, Herbert Y Meltzer, Aristotle N Voineskos, Gary Remington, James L Kennedy
OBJECTIVES: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed. METHODS: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD. RESULTS: We found the ERBB4 rs839523 CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P = ...
April 10, 2017: World Journal of Biological Psychiatry
https://www.readbyqxmd.com/read/28387387/deutetrabenazine-treatment-of-hyperkinetic-aspects-of-huntington-s-disease-tardive-dyskinesia-and-tourette-syndrome
#6
D M Paton
Deutetrabenazine is a derivative of tetrabenazine in which two trideuteromethoxy groups substitute two methoxy groups. The active metabolites of deutetrabenazine have a longer half-life than those of tetrabenazine, together with a greater overall absorption. However, the peak plasma concentrations are lower. Because of these pharmacokinetic differences, deutetrabenazine can be given twice daily, thus improving compliance. The lower peak concentrations may account for a lower incidence of some unwanted adverse effects...
February 2017: Drugs of Today
https://www.readbyqxmd.com/read/28382107/tetrabenazine-in-treatment-of-hyperkinetic-movement-disorders-an-observational-study
#7
Rita Miguel, Marcelo D Mendonça, Raquel Barbosa, Filipa Ladeira, Tânia Lampreia, José Vale, Paulo Bugalho
BACKGROUND: Tetrabenazine (TBZ) is commonly used in hyperkinetic movement disorders. In this retrospective study, we aimed to assess the TBZ effectiveness and adverse events (AEs) in Huntington disease (HD), vascular chorea, tics, dystonia, tardive oromandibular (OM) dyskinesia and other tardive syndromes (TS). METHODS: Qualitative analysis of clinical response was used to estimate TBZ effectiveness. TBZ-associated AE frequency and subsequent discontinuation rate were used to estimate tolerability; the tolerability profile was measured through the TBZ minimal dose and exposure time required to elicit AEs...
February 2017: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/28377723/multiple-psychopharmacological-effects-of-the-traditional-japanese-kampo-medicine-yokukansan-and-the-brain-regions-it-affects
#8
REVIEW
Kazushige Mizoguchi, Yasushi Ikarashi
Yokukansan (YKS), a traditional Japanese Kampo medicine, has indications for use in night crying and irritability in children, as well as neurosis and insomnia. It is currently also used for the remedy of the behavioral and psychological symptoms of dementia (BPSD), such as aggressiveness, agitation, and hallucinations. In parallel with clinical evidence, a significant amount of fundamental researches have been undertaken to clarify the neuropsychopharmacological efficacies of YKS, with approximately 70 articles, including our own, being published to date...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28375082/co-treatment-with-imipramine-averted-haloperidol-instigated-tardive-dyskinesia-association-with-serotonin-in-brain-regions
#9
Noreen Samad, Farzana Yasmin, Darakhshan Jabeen Haleem
Outcome of imipramine (IMI) treatment was scrutinized on progression of haloperidol instigated tardive dyskinesia (TD). 0.2 mg/kg/rat dosage of haloperidol provided orally to rats for 2 weeks enhanced vacuous chewing movements that escalated when the process proceeded for 5 weeks. Following 2 weeks co-injection 5 mg/kg dosage of IMI was diminished haloperidol-instigated VCMs and fully averted following five weeks. The potency of 8-OH-DPAT-instigated locomotor activity exhibited higher in saline+haloperidol treated rats while not observed in IMI+ haloperidol treated rats...
November 2016: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28374238/antioxidant-effects-of-rice-bran-oil-mitigate-repeated-haloperidol-induced-tardive-dyskinesia-in-male-rats
#10
Noreen Samad, Darakhshan Jabeen Haleem
Tardive dyskinesia (TD) is associated with the use of antipsychotic drugs such as D2 antagonist haloperidol (HP). The chronic use of HP is involved in the causation of free radicals and/or oxidative stress. In view of the nootropic, anti-anxiety, anti-inflammatory-like effects of rice bran oil (RBO) in a variety of investigations, we assessed the protective properties of RBO on HP-induced TD and neurochemical alteration. Rats treated with HP orally at a dose of 0.2 mg/kg/day for a period of 5 weeks developed VCMs which increased progressively as the treatment continued for 5 weeks...
April 3, 2017: Metabolic Brain Disease
https://www.readbyqxmd.com/read/28360793/withdrawal-emergent-dyskinesia-and-supersensitivity-psychosis-due-to-olanzapine-use
#11
Hakan Karaş, Mehmet Güdük, Ömer Saatcioğlu
Tardive dyskinesia (TD) usually appears after years of antipsychotic drug use and appears to be related to the total lifetime medication dose. In withdrawal-emergent dyskinesia (WE-D), which is considered to be a subtype of TD, dyskinetic symptoms often appear shortly after a rapid reduction in antipsychotic drug dose or sudden discontinuation of the drug. Supersensitivity psychosis, which is frequently observed along with TD and is considered to have a similar etiology as TD, is a psychotic relapse phenomenon that occurs after the withdrawal of an antipsychotic drug or a rapid reduction in the drug dosage...
June 2016: Noro Psikiyatri Arsivi
https://www.readbyqxmd.com/read/28348731/clonazepam-improves-dopamine-supersensitivity-in-a-schizophrenia-patient-a-case-report
#12
REVIEW
Mina Fukai, Tetsu Hirosawa, Tetsuya Takahashi, Reizo Kaneda, Mitsuru Kikuchi, Yoshio Minabe
Dopamine supersensitivity is an important consideration for assessing treatment-resistant schizophrenia. The emergence of dopamine supersensitivity might be related to upregulation of dopamine D2 receptor, which engenders tolerance to antipsychotics, rebound psychosis, and tardive dyskinesia (TD). A 24-year-old man with a history of treatment-resistant schizophrenia was hospitalized for treatment of bone fracture sustained during a suicide attempt. After the operation, his clinical symptoms implied malignant catatonia...
March 2017: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/28335658/dopamine-antagonists-for-treatment-resistance-in-autism-spectrum-disorders-review-and-focus-on-bdnf-stimulators-loxapine-and-amitriptyline
#13
REVIEW
Jessica A Hellings, L Eugene Arnold, Joan C Han
Drug development and repurposing are urgently needed for individuals with autism spectrum disorders (ASD) and psychiatric comorbidity, which often presents as aggression and self-injury. Areas covered: We review dopamine antagonists, including classical and atypical, as well as unconventional antipsychotics in ASD. The older antipsychotic loxapine is discussed in terms of preliminary albeit limited evidence in ASD. Emerging promise of amitriptyline in ASD is discussed, together with promising BDNF effects of loxapine and amitriptyline...
April 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28329449/behavioural-and-neurochemical-effects-of-alpha-lipoic-acid-associated-with-omega-3-in-tardive-dyskinesia-induced-by-chronic-haloperidol-in-rats
#14
Dayane Pessoa Araújo, Thaisa Camboim, Ana Silva, Caio Fonseca, Rebeca Sousa, Mabson Barbosa, Lucidio Oliveira, José Cavalcanti, Eudes Lucena, Fausto Guzen
Tardive dyskinesia (TD) is characterized by involuntary movements of the lower portion of the face being related to typical antipsychotic therapy. TD is associated with the oxidative imbalance in the basal ganglia. Lipoic acid (LA) and omega 3 (ω-3) are antioxidants acting as enzyme cofactors, regenerating antioxidant enzymes. This study aimed to investigate behavioral and neurochemical effects of supplementation with of LA (100mg/Kg) and ω-3 (1g/Kg) in the treatment of TD-induced by chronic use haloperidol (HAL) (1mg/Kg) in rats...
March 22, 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28320223/kinect-3-a-phase-3-randomized-double-blind-placebo-controlled-trial-of-valbenazine-for-tardive-dyskinesia
#15
Robert A Hauser, Stewart A Factor, Stephen R Marder, Mary Ann Knesevich, Paul M Ramirez, Roland Jimenez, Joshua Burke, Grace S Liang, Christopher F O'Brien
OBJECTIVE: Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics. Valbenazine (NBI-98854) is a novel, highly selective vesicular monoamine transporter 2 inhibitor that demonstrated favorable efficacy and tolerability in the treatment of tardive dyskinesia in phase 2 studies. This phase 3 study further evaluated the efficacy, safety, and tolerability of valbenazine as a treatment for tardive dyskinesia. METHOD: This 6-week, randomized, double-blind, placebo-controlled trial included patients with schizophrenia, schizoaffective disorder, or a mood disorder who had moderate or severe tardive dyskinesia...
March 21, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28297686/-early-experience-with-the-vercise-sup-tm-sup-dbs-system-in-the-treatment-of-dystonic-tremor
#16
Yasushi Miyagi
Six cases of dystonic tremor were treated with the Vercise<sup>TM</sup> deep brain stimulation(DBS)system, which has the multiple independent current control(MICC)technology. The mean preoperative score of Burke-Fahn-Marsden dystonia rating scale was 16.2±9.4, which was reduced to 6.1±4.6 at 5 months postoperatively. A 65-year-old male presented an intractable dystonic tremor of the jaw, neck, and shoulders due to tardive syndrome. He experienced the successful tremor relief after unipolar DBS in the globus pallidus internus(GPi)with Vercise<sup>TM</sup> but complained of dysarthria...
March 2017: No Shinkei Geka. Neurological Surgery
https://www.readbyqxmd.com/read/28291037/tardive-dyskinesia-a-historical-perspective
#17
Matthew Macaluso, Alexandra Flynn, Sheldon H Preskorn
The goal of this column is to provide historical context on tardive dyskinesia (TD) to help the reader understand how the concept was studied and evolved over time. Psychiatrists today should understand this history and consider it in combination with more recent data on the neurobiology of TD, including data from animal studies. This combination of classic data with modern science can help readers develop a more complete understanding and lead to a more judicious use of the term TD, after consideration of all of the alternative causes of abnormal movements, including spontaneous dyskinesia (SD)...
March 2017: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/28276538/valbenazine-for-the-treatment-of-tardive-dyskinesia
#18
N Barquero
Valbenazine (NBI-98854, Ingrezza) is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that modulates dopamine release during nerve communication. The pharmacological target VMAT2 may play an important role in the treatment of tardive dyskinesia (TD), an iatrogenic condition associated with the administration of antipsychotic medication for long periods and characterized by rapid, repetitive, stereotypic, involuntary movements of the face and extremities. There are currently no Food and Drug Administration (FDA)-approved drugs for the treatment of TD...
December 2016: Drugs of Today
https://www.readbyqxmd.com/read/28262410/-platypnea-orthodeoxia%C3%A2-a-report-of-two-cases
#19
V Mercier, G Tragas, P Compère, P Lefebvre, A Van Meerhaeghe
The plathypnea orthodeoxia syndrome is a rare condition that is characterized by dyspnea and hypoxia that occurs in the upright position and improves with recumbency. The diagnostic is often made tardively and requires the combination of two components: a mechanical one (for example a patent foramen ovale) and a kinetic one (for example COPD). This combination contributes to the blood flow through the communication. The treatment consists of closing the veno-arterial communication (in the case of a patent foramen ovale, the closing of the inter-atrial septum) (Knapper et al, 2014)...
April 2017: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/28254105/a-single-case-of-tourette-s-syndrome-treated-with-traditional-chinese-medicine
#20
Min-Hwa Lee
The objective of this case study was to investigate the effectiveness of Chinese medicine in treating Tourette's syndrome. Tourette's syndrome is a childhood- onset disorder that is characterized by sudden, involuntary movements or tics. The participant in this study was a 33-year-old male who had been diagnosed with Tourette's syndrome at the age of 9 years. His major complaints included facial tics, shoulder shrugging, and clearing the throat. Using a combination of acupuncture, herbs, Gua-Sha, and lifestyle changes once a week for 35 treatments, all the symptoms were reduced by 70%, as reported by the patient...
January 2017: Journal of Acupuncture and Meridian Studies
keyword
keyword
112950
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"